NEW YORK--(BUSINESS WIRE)--OMRIX Biopharmaceuticals, Inc. (“OMRIX” or “The Company”) (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and passive immunotherapy products, announced today that it has initiated enrollment of patients in a Phase I/II clinical trial for Adhexil™, the Company’s proprietary adhesion prevention product. The study will evaluate the safety and initial efficacy of Adhexil in preventing and/or reducing post-operative adhesions in patients undergoing gynecological surgery of the ovaries. The clinical trial will be conducted over a one-year period and will enroll 25 patients with bilateral ovarian disease and identified adhesions across four centers in Europe and the U.S.
